医学
烟酰胺
肾脏疾病
内分泌学
内科学
肾
肾损伤
烟酰胺磷酸核糖转移酶
烟酰胺
糖尿病
疾病
糖尿病肾病
急性肾损伤
动物模型
药理学
烟酰胺单核苷酸
肾功能
拉顿
人肾
作者
Maria Strömstedt,Wenjun Ju,Yu-feng Huang,Anders M Johansson,Lars Löfgren,Birgitta E. Rosengren,Fredrik H Bergström,Pär Nordell,Viji Nair,Sean F. Eddy,Jeffrey B. Hodgin,Anna Reznichenko,Pernille Hansen,Ola Fjellström,Matthias Kretzler
标识
DOI:10.1681/asn.20257za33bc1
摘要
Background: Therapeutic strategies for chronic kidney disease (CKD) linked directly to the understanding of intra-kidney pathophysiology and progression are limited. A molecular signature linked to CKD progression was used to identify and develop a new class of treatment options. Methods: A transcriptome-driven analysis of kidney biopsies from CKD patients with longitudinal follow up (N=309) was used to identify genes associated with disease severity and progression, which was evaluated by GFR slope and composite endpoint of kidney failure and 40% GFR reduction. Expression of NNMT was determined using single cell analysis and in situ hybridization. A small molecule inhibitor was identified, and its effects on renal cells and kidney injury in uninephrectomized (UNx) diabetic db/db mice were investigated. Results: NNMT was identified as one of the strongest predictors of baseline GFR (r=-0.66, FDR<0.05) in a genome-wide profiling study of kidney biopsies in European Renal cDNA Biobank. NNMT expression was detected in both glomeruli and tubulointerstitium. Tubulointerstitial NNMT mRNA at the time of biopsy was significantly (p<0.0001) correlated with interstitial fibrosis (r=0.64) and tubular atrophy (r=0.58). Association of NNMT with kidney disease progression was demonstrated by 1) its significant correlation with GFR slope (<0.0001); 2) higher NNMT is associated with increased risk of progression to composite endpoint in two CKD cohorts, C-PROBE and NEPTUNE. Overexpression of NNMT in HEK cells decreased cellular NAD+ levels. A novel small molecule NNMT inhibitor, AZ'8413, restored NAD+ levels in NNMT-overexpressing cells and increased NAD+ in human proximal tubule cells. In db/db UNx mice, AZ'8413 decreased the progression of glomerular mesangial expansion and tubular injury. Kidney expression of Sirt1 increased, while ROS-producing enzymes and urinary markers of lipid peroxidation decreased. Conclusion: Our integrative study identifies NNMT as a promising target and validates NNMT inhibitors as novel therapeutics for mitigating CKD progression. Funding: Commercial Support - AstraZeneca
科研通智能强力驱动
Strongly Powered by AbleSci AI